Genentech Gets FDA Breakthrough Designation for Gazyva in Lupus Nephritis

Date : 09/18/2019 @ 10:40AM
Source : Dow Jones News
Stock : Roche Holdings Ltd AG (QX) (RHHBY)
Quote : 43.86  -0.87 (-1.95%) @ 8:59PM
After Hours
Last Trade
Last $ 43.86 ◊ 0.00 (0.00%)

Genentech Gets FDA Breakthrough Designation for Gazyva in Lupus Nephritis

Historical Stock Chart

6 Months : From Aug 2019 to Feb 2020

Click Here for more Roche (QX) Charts.

By Colin Kellaher


Roche Holding AG's (ROG.EB) Genentech unit Wednesday said the U.S. Food and Drug Administration granted breakthrough-therapy designation to Gazyva for adults with lupus nephritis, a potentially life-threatening inflammation of the kidneys.

Genentech said the designation is based on a phase II study in which Gazyva in combination with standard of care showed enhanced efficacy compared to placebo in achieving complete renal response at one year.

The FDA's breakthrough-therapy designation aims to expedite the development and review of a drug for serious conditions when preliminary clinical evidence shows the drug may show substantial improvement over available therapies.

There are currently no FDA-approved medicines for lupus nephritis, Genentech said.


Write to Colin Kellaher at


(END) Dow Jones Newswires

September 18, 2019 06:25 ET (10:25 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest RHHBY Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.